Cassava Sciences (SAVA) Stock Climbs On New Data

Cassava Sciences SAVA Stock News

Cassava Sciences Inc (NASDAQ: SAVA) is headed up in the market this morning after announcing positive new data from a Phase 2b clinical study of sumifilam. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

SAVA Stock Climbs On Sumifilam Data

In the press release, Cassava Sciences provided new clinical data from a Phase 2b clinical study. The study is assessing sumifilam in patients with Alzheimer’s disease, and showing incfredible promise in the process.

Importantly, the clinical study is being funded by the National Institutes of Health (NIH).

In the study, the SAVA said data show a decrease in levels of a protein called HMGB1 and improved measurements of the integrity of the blood-brain barrier. This is a major breakthrough as no drug candidate in science literature has shown an ability to decrease HMGB1 and improve BBB integrity in patients with Alzheimer’s disease.

Sumifilam is a small molecule drug that restores the normal shape and function of altered filamin A protein in the brain. It is believed that by restoring the shape and function of this protein in the brain, the treatment will lead to improved quality and length of life for Alzheimer’s disease patients.

In a statement, Remi Barbier, President and CEO at SAVA, had the following to offer:

The ability to improve multiple biomarkers of disease with one drug is a unique achievement. We believe these exciting clinical results create a time of rapid strategic momentum for the Company, to include development plans to evaluate sumifilam in a Phase 3 clinical program in patients with Alzheimer’s disease.

This Is HUGE!

The news released by Cassava Sciences this morning proved to be overwhelmingly positive. Keep in mind, Alzheimer’s disease is an incredibly difficult to treat condition. While there are treatments on the market, the effectiveness of those treatments is a hotly debated topic.

If SAVA is able to prove that sumifilam is more effective than other, currently available options, it could quickly take the lion’s share of the market, and the market is massive. By 2023, it’s expected that the Alzheimer’s disease market will grow to be worth well over $13 billion per year. Considering the fact that the stock trades with a market cap of $229 million, it doesn’t need to take the whole market here to generate meaningful revenue. Nonetheless, the potential for sumifilam to take the lion’s share of the market suggests that the company is working on a blockbuster.

All in all, if you’re not watching SAVA stock closely, you’re likley missing out.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don't Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.